Trial Profile
An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations who participated in studies ACZ885G2301 and ACZ885G2305; and response characterisation study in canakinumab treatment-naive patients with active SIJA with and without fever (Cohort 2 (treatment naive patients) only applicable in countries where approved)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Beta-SPECIFIC-3; G2301E1
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Feb 2021 Results (n=54) assessing identification of potential serum biomarkers predicting response to canakinumab therapy in SJIA patients, published in the Rheumatology.
- 10 Jul 2020 Results (n=123) assessing long-term efficacy, safety of canakinumab and explore prediction of response in systemic juvenile idiopathic arthritis patients with and without fever, published in the Arthritis and Rheumatology.
- 02 Mar 2018 Results pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046), were published in the Clinical and Experimental Rheumatology.